Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
AMRX has more than doubled off its 52-week low of $6.685.
Summary
Amneal Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, meeting or exceeding all guidance metrics. Fourth quarter net revenue increased 11% year-over-year to $814 million, while full year net revenue grew 8% to $3.02 billion. The company also provided optimistic 2026 financial guidance, projecting net revenue between $3.05 billion and $3.15 billion and adjusted diluted EPS of $0.93 to $1.03. This comprehensive earnings release serves as the primary source for the subsequent news reports from Reuters and Dow Jones, which highlighted the Q4 revenue beat and the 2026 guidance figures. The positive performance and outlook are likely to be viewed favorably by the market, suggesting continued operational strength. Traders will now focus on the market's reaction to this guidance and the company's execution against its 2026 projections.
At the time of this announcement, AMRX was trading at $14.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $6.69 to $15.42. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.